[{"address1": "Times Square Tower", "address2": "Suite 2503 7 Times Square", "city": "New York", "state": "NY", "zip": "10036", "country": "United States", "phone": "646 200 5278", "website": "https://www.sellaslifesciences.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.", "fullTimeEmployees": 16, "companyOfficers": [{"maxAge": 1, "name": "Dr. Angelos M. Stergiou M.D., ScD h.c.", "age": 47, "title": "Founder, President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 904243, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John Thomas Burns CPA", "age": 38, "title": "Senior VP & CFO", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 505158, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stacy E. Yeung", "title": "VP, Associate General Counsel & Head of Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dragan  Cicic M.D., MBA", "age": 60, "title": "Senior Vice President of Clinical Development", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 466430, "exercisedValue": 0, "unexercisedValue": 55739}, {"maxAge": 1, "name": "Mr. Andrew  Elnatan", "title": "VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.2, "open": 1.22, "dayLow": 1.175, "dayHigh": 1.22, "regularMarketPreviousClose": 1.2, "regularMarketOpen": 1.22, "regularMarketDayLow": 1.175, "regularMarketDayHigh": 1.22, "beta": 2.409, "forwardPE": -2.2, "volume": 308463, "regularMarketVolume": 308463, "averageVolume": 982883, "averageVolume10days": 1023410, "averageDailyVolume10Day": 1023410, "bid": 1.19, "ask": 1.22, "bidSize": 600, "askSize": 600, "marketCap": 77591256, "fiftyTwoWeekLow": 0.5, "fiftyTwoWeekHigh": 1.9, "fiftyDayAverage": 1.2332, "twoHundredDayAverage": 1.09435, "currency": "USD", "enterpriseValue": 52269464, "floatShares": 54645980, "sharesOutstanding": 64125000, "sharesShort": 9721745, "sharesShortPriorMonth": 7553435, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.1683, "heldPercentInsiders": 0.0024899999, "heldPercentInstitutions": 0.13754, "shortRatio": 8.52, "shortPercentOfFloat": 0.16870001, "bookValue": 0.172, "priceToBook": 7.0348835, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -35809000, "trailingEps": -1.08, "forwardEps": -0.55, "lastSplitFactor": "1:50", "lastSplitDate": 1573171200, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SLS", "underlyingSymbol": "SLS", "shortName": "SELLAS Life Sciences Group, Inc", "longName": "SELLAS Life Sciences Group, Inc.", "firstTradeDateEpochUtc": 1205328600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d5f0c150-9f89-3f17-8497-1832af4e7670", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.21, "targetHighPrice": 7.5, "targetLowPrice": 4.0, "targetMeanPrice": 5.83, "targetMedianPrice": 6.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 18415000, "totalCashPerShare": 0.319, "totalDebt": 801000, "quickRatio": 1.276, "currentRatio": 1.489, "debtToEquity": 8.271, "returnOnAssets": -0.84596, "returnOnEquity": -3.1338599, "freeCashflow": -28920624, "operatingCashflow": -30044000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-11"}]